San Diego – September 11, 2026 -- Shareholder rights firm Robbins LLP has filed a class action against Unicycive Therapeutics, Inc. (NASDAQ: UNCY) on behalf of investors who purchased the biotech's securities between December 29, 2025 and June 29, 2026, after the FDA rejected the company's kidney disease drug for a second time over unresolved manufacturing deficiencies.

San Diego – September 10, 2026 -- Robbins LLP has filed a securities class action against Beta Bionics, Inc. (NASDAQ: BBNX) on behalf of investors who purchased common stock between July 30, 2025 and February 24, 2026, alleging the company misrepresented the safety and commercial viability of its iLet Bionic Pancreas insulin pump.